KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Receives $32.60 Consensus Target Price from Brokerages

Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) have earned an average rating of “Moderate Buy” from the eight brokerages that are currently covering the company, MarketBeat reports. One research analyst has rated the stock with a sell recommendation and seven have assigned a buy recommendation to the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $32.60.

Several equities research analysts have weighed in on KALV shares. HC Wainwright upped their target price on KalVista Pharmaceuticals from $27.00 to $37.00 and gave the stock a “buy” rating in a report on Friday, January 9th. Weiss Ratings restated a “sell (d-)” rating on shares of KalVista Pharmaceuticals in a research note on Thursday, January 22nd. Wall Street Zen downgraded KalVista Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Sunday. Citizens Jmp lowered their price objective on shares of KalVista Pharmaceuticals from $29.00 to $28.00 and set a “market outperform” rating for the company in a research note on Thursday, March 26th. Finally, Needham & Company LLC raised their target price on shares of KalVista Pharmaceuticals from $35.00 to $36.00 and gave the company a “buy” rating in a research report on Wednesday, March 25th.

Insider Activity

In related news, CFO Brian Piekos sold 1,767 shares of the business’s stock in a transaction that occurred on Monday, February 23rd. The shares were sold at an average price of $15.57, for a total value of $27,512.19. Following the completion of the transaction, the chief financial officer owned 13,762 shares of the company’s stock, valued at $214,274.34. The trade was a 11.38% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Benjamin L. Palleiko sold 10,034 shares of the company’s stock in a transaction on Monday, February 23rd. The stock was sold at an average price of $15.57, for a total value of $156,229.38. Following the sale, the chief executive officer owned 442,883 shares of the company’s stock, valued at approximately $6,895,688.31. This represents a 2.22% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 248,009 shares of company stock valued at $4,213,467. 4.30% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the stock. BNP Paribas Financial Markets lifted its stake in shares of KalVista Pharmaceuticals by 47.0% during the 2nd quarter. BNP Paribas Financial Markets now owns 4,041 shares of the specialty pharmaceutical company’s stock worth $46,000 after purchasing an additional 1,292 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in KalVista Pharmaceuticals in the third quarter valued at about $55,000. Wolverine Asset Management LLC bought a new position in KalVista Pharmaceuticals in the third quarter worth about $57,000. KLP Kapitalforvaltning AS bought a new position in KalVista Pharmaceuticals in the third quarter worth about $63,000. Finally, Truvestments Capital LLC lifted its position in shares of KalVista Pharmaceuticals by 253.8% during the fourth quarter. Truvestments Capital LLC now owns 4,684 shares of the specialty pharmaceutical company’s stock valued at $76,000 after buying an additional 3,360 shares during the last quarter.

KalVista Pharmaceuticals Price Performance

Shares of NASDAQ:KALV opened at $19.90 on Wednesday. KalVista Pharmaceuticals has a 52-week low of $9.23 and a 52-week high of $21.31. The stock has a market cap of $1.02 billion, a P/E ratio of -5.04 and a beta of -0.40. The business’s 50 day moving average is $16.44 and its 200 day moving average is $14.65. The company has a quick ratio of 7.21, a current ratio of 7.22 and a debt-to-equity ratio of 8.18.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.